TriSalus Life Sciences (NASDAQ:TLSI) Upgraded to “Strong-Buy” at HC Wainwright

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by equities research analysts at HC Wainwright to a “strong-buy” rating in a report issued on Wednesday, Zacks reports.

A number of other research firms have also commented on TLSI. Lake Street Capital lowered their price objective on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.67.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $4.76 on Wednesday. TriSalus Life Sciences has a 12-month low of $2.20 and a 12-month high of $7.95. The company’s 50 day moving average price is $4.75 and its two-hundred day moving average price is $4.33. The firm has a market cap of $293.12 million, a PE ratio of -3.66 and a beta of 0.44. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). The business had revenue of $11.41 million during the quarter, compared to analyst estimates of $10.27 million.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds have recently modified their holdings of TLSI. First Light Asset Management LLC acquired a new position in TriSalus Life Sciences in the 1st quarter worth about $20,267,000. BlackRock Inc. bought a new position in TriSalus Life Sciences in the second quarter valued at about $12,099,000. Nantahala Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the second quarter valued at about $10,900,000. Wasatch Advisors LP acquired a new stake in shares of TriSalus Life Sciences during the first quarter valued at about $5,752,000. Finally, Vanguard Group Inc. grew its holdings in shares of TriSalus Life Sciences by 42.4% during the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after purchasing an additional 345,186 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.